Vericel is expected to report Q3 2026 revenue of $66.4 million and EPS of $0.02, with the current stock price of $58.12 trading at a discount to the average analyst price target of $64.50. Investors are primarily focused on the growth trajectory of MACI revenue, which serves as the company's primary growth engine in the sports medicine market. Performance in the quarter is expected to reflect continued expansion of the sales force and increased uptake of NexoBrid within burn centers. This report is critical for confirming Vericel's path toward sustained profitability as it leverages its commercial infrastructure across both its cartilage repair and advanced skin care franchises.